Severe Asthma Reduced in Phase 3 Benralizumab Tests

AstraZeneca recently announced that the new severe asthma medicine benralizumab met the primary endpoints in two Phase 3 registration trials. Findings of the trials called SIROCCO and CALIMA, revealed that the monoclonal antibody compound was well tolerated and demonstrated significant reductions in the annual asthma exacerbation rate compared to placebo. The positive results will be presented at a future medical conference. According to the Centers for Disease…

This content is for members only.
Log In Register


Email and we'll get back to you, asap.


©2015 SpiroHub - all rights reserved


Log in with your credentials


Forgot your details?